Structure Therapeutics Q2 FY26 net loss widens to $106.16 million; R&D expenses rise to $100.06 million

Reuters2026/08/06 20:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Structure Therapeutics posted a Q2 net loss of $106.16 million, widening from $61.66 million a year earlier.
R&D expense climbed to $100.06 million from $54.71 million; G&A rose to $18.57 million from $15.74 million.
Cash, cash equivalents and short-term investments fell to $1.34 billion as of June 30, 2026, from $1.45 billion at year-end 2025.
First patients were dosed in the Phase 3 ACCOMPLISH-1 and -2 program for aleniglipron in chronic weight management.
Initial Phase 1 ACCG-2671 SAD data and a MAD trial start are targeted for Q3 2026; ACCESS OLE topline 72-week data are also due Q3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805469) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Structure Therapeutics Q2 FY26 net loss widens to $106.16 million; R&D expenses rise to $100.06 million

You may also like

Crypto prices